Decreased Intragastric Acid Concentration as an Approach to Peptic Disease Therapy
Recent research has focused on the pathophysiology of peptic ulcer disease (Fig. 1), and this includes factors such as the changing demographics of ulcer disease, modern methods of ulcer diagnosis, natural history, and the current status of surgery in patients with peptic ulcer disease. The importance of the gastric mucosal barrier has been examined, as has the role of prostaglandins in mucosal protection in health and disease.
KeywordsDuodenal Ulcer Acid Secretion Peptic Ulcer Disease Ulcer Healing Acid Suppression
Unable to display preview. Download preview PDF.
- 1.Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers: A model of the relationship between ulcer healing and acid suppression. Gastroenterology 99:345–351, 1990. It is the duration that the intragastric pH is above 3 that is important for DU healing: it is not necessary to achieve more potent acid inhibition.PubMedGoogle Scholar
- 2.Johnston DA, Marks IN, Young GO, et al: Duodenal ulcer healing and acid secretory responses to modified sham feeding and pentagastrin stimulation. Aliment Pharmacol Ther 4:403–410, 1990. DU healing with sucralfate results in decreased acid secretory responses to vagal and pentagastrin stimulation.PubMedCrossRefGoogle Scholar
- 3.Jones DB, Howden CW, Burget DW, el al: Acid suppression in duodenal ulcer: A meta-analysis to define optimal dosing with antisecretory drugs. Gut 28:1120–1127, 1987. The duration of acid suppression is important to predict the rate of DU healing after varying periods of treatment.PubMedCrossRefGoogle Scholar
- 4.Kummer AF, Johnston DA, Marks IN, et al: Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine. Gut 33:175–178, 1992. Acid secretion in DU patients falls after ulcer healing is achieved by healing with either of these medications.PubMedCrossRefGoogle Scholar
- 5.Savarino V, Mela GS, Zentilin P, et al: Lack of gastric acid rebound after stopping a successful shortterm course of Nizatidine in duodenal ulcer patients. Am J Gastroenterol 86:281–284, 1991. Acid rebound may not be the problem that it was once thought to be—at least not with this H2-receptor antagonist.PubMedGoogle Scholar